Supportive Care in Cancer

, Volume 19, Issue 2, pp 231–237 | Cite as

Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE

  • John B. Bossaer
  • Philip D. HallEmail author
  • Elizabeth Garrett-Mayer
Original Article



This study seeks to determine the incidence of vancomycin-resistant enterococci (VRE) infection in high-risk neutropenic fever patients colonized with VRE and to determine patient characteristics associated with VRE infection.


We conducted a retrospective, single-center, unmatched case-control study. Fifty-three VRE-colonized, high-risk patients with neutropenic fever were identified between January 2006 and February 2009. The two most common diagnoses/conditions included acute myeloid leukemia and hematopoietic stem cell transplantation. Data collected included days of neutropenia, days of fever, demographic data, culture results, and antimicrobial therapy.


Twenty of the 53 patients (38%) with VRE colonization developed a VRE infection. The most common VRE infections were bacteremias (26%). The presence of neutropenia lasting longer than 7 days was associated with the development of VRE infection in this high-risk population colonized with VRE. The timeframe to develop VRE infection varied from 1 day to 2 weeks.


For patients colonized with VRE, approximately 38% of high-risk neutropenic patients developed a VRE infection. This is the first study to specifically evaluate the incidence of VRE infections in febrile neutropenic patients colonized with VRE. Future research into the use and efficacy of empiric VRE coverage is needed.


Vancomycin-resistant enterococci (VRE) Febrile neutropenia Daptomycin Linezolid 



febrile neutropenia


vancomycin-resistant enterococci


hematopoietic stem cell transplantation


blood stream infection


absolute neutrophil count


  1. 1.
    Hughes WT, Armstrong D, Bodey GP et al (2002) Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751PubMedCrossRefGoogle Scholar
  2. 2.
    National Comprehensive Cancer Network. 2008 Prevention and treatment of cancer-related infections. [] Accessed 12/11/08
  3. 3.
    Bhavnani SM, Drake JA, Forrest A et al (2000) A nationwide, multicenter, case-control study comparing risk factors, treatment and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis 36:145–158PubMedCrossRefGoogle Scholar
  4. 4.
    Vergis EN, Hayden MK, Chow JW et al (2001) Determination of vancomycin resistance and mortality rates in enterococcal bacteremia: a prospective multicenter study. Ann Intern Med 135:484–492PubMedGoogle Scholar
  5. 5.
    DiazGranados CA, Jernigan JA (2005) Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. Jour Infect Dis 191:588–595CrossRefGoogle Scholar
  6. 6.
    Olivier CN, Blake RK, Steed LL et al (2008) Risk of vancomycin-resistant enterococcus (VRE) bloodstream infection among patients colonized with VRE. Infect Control Hosp Epidemiol 29:404–409PubMedCrossRefGoogle Scholar
  7. 7.
    Zaas AK, Song X, Tucker P et al (2002) Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci. Clin Infect Dis 35:1139–1146PubMedCrossRefGoogle Scholar
  8. 8.
    Matar MJ, Tarrand J, Raad I et al (2006) Colonization and infection with vancomycin-resistant enterococcus among patients with cancer. Am Jour Infect Control 34:534–536CrossRefGoogle Scholar
  9. 9.
    Weinstock DM, Conlon M, Iovino C et al (2007) Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant 13:615–621PubMedCrossRefGoogle Scholar
  10. 10.
    Pertel PE, Bernado P, Fogarty C et al (2008) Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis 46:1142–1151PubMedCrossRefGoogle Scholar
  11. 11.
    Gerson SL, Kaplan SL, Bruss JB et al (2002) Hematolog effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 46:2723–2726PubMedCrossRefGoogle Scholar
  12. 12.
    Poutsiaka DD, Skiffington S, Miller KB et al (2007) Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. Jour Infect 54:567–571CrossRefGoogle Scholar
  13. 13.
    Smith PF, Birmingham MC, Noskin GA et al (2003) Safety, efficacy, and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia. Ann Oncol 14:795–801PubMedCrossRefGoogle Scholar
  14. 14.
    Jaksic B, Martinelli G, Perez-Oteyza J et al (2006) Efficacy and safety of linezolid compared to vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 42:597–607PubMedCrossRefGoogle Scholar
  15. 15.
    Poutsiaka DD, Skiffington S, Miller KB et al (2007) Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. Jour of Infect 54:567–571CrossRefGoogle Scholar
  16. 16.
    Eys A, Rapoport BL, Anderson R (2004) Febrile neutropenia: a prospective study to validate the Multinational Associatation of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer 12:555–560Google Scholar
  17. 17.
    Dubberke ER, Hollands JM, Georgantopoulos P et al (2006) Vancomycin-resistant enterococcal bloodstream infections on a hematopoietic stem cell transplant unit: are the sick getting sicker? Bone Marrow Transplant 38:813–819PubMedCrossRefGoogle Scholar
  18. 18.
    Rostein C, Mandell LA, Goldberg N (1997) Fluoroquinolone prophylaxis for profoundly neutropenic cancer patients: a meta-analysis. Curr Opin Oncol 4(Suppl 2):S2–S7Google Scholar
  19. 19.
    Cruciani M, Rampazzo R, Malena M et al (1996) Prophylaxis with fluoroquinolones in neutropenic patients: a meta-analysis. Clin Infect Dis 23:795–805PubMedCrossRefGoogle Scholar
  20. 20.
    Carratala J, Fernandez-Sevilla A, Tubau F et al (1995) Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who received prophylactic norfloxacin. Clin Infect Dis 20:557–560PubMedCrossRefGoogle Scholar
  21. 21.
    Kern WV, Andriof E, Oethinger M et al (1994) Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 38:681–687PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • John B. Bossaer
    • 1
  • Philip D. Hall
    • 2
    • 4
    Email author
  • Elizabeth Garrett-Mayer
    • 3
  1. 1.Department of Pharmacy Practice, Bill Gatton College of PharmacyEast Tennessee State UniversityJohnson CityUSA
  2. 2.Department of Clinical Pharmacy and Outcomes Sciences, South Carolina College of PharmacyMedical University of South CarolinaCharlestonUSA
  3. 3.Hollings Cancer CenterMedical University of South CarolinaCharlestonUSA
  4. 4.South Carolina College of Pharmacy274 Calhoun Street, MSC 141CharlestonUSA

Personalised recommendations